Distribution of paclitaxel in plasma and cerebrospinal fluid

Anti-Cancer Drugs

Volumn 14, Issue 5, 2003, Pages 365-368

  Gelderblom, Hans ^a,c   Baker, Sharyn D ^b   Zhao, Ming ^b   Verweij, Jaap ^a   Sparreboom, Alex ^a,d  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cerebrospinal fluid; Cremophor EL; Mass spectrometry; Paclitaxel; Pharmacokinetics

Indexed keywords

CIMETIDINE; CLEMASTINE; CREMOPHOR; DEXAMETHASONE; DOCETAXEL; GLICLAZIDE; PACLITAXEL; PANTOPRAZOLE; TAMOXIFEN; TEMAZEPAM; TOLBUTAMIDE;

ADULT; ARTICLE; BREAST CANCER; CANCER PATIENT; CASE REPORT; CEREBROSPINAL FLUID ANALYSIS; CLINICAL STUDY; COLORIMETRY; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG HALF LIFE; EQUILIBRIUM DIALYSIS; EVALUATION; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PLASMA CLEARANCE; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; BREAST NEOPLASMS; FEMALE; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; MODELS, BIOLOGICAL; PACLITAXEL;

EID: 0038178861     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200306000-00007     Document Type: Article

References (16)

1. Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001; 37:1590-1598.
2. Henningsson A, Karlsson MO, Vigano L, Gianni L, Verweij J, Sparreboom A. Mechanism-based pharmacokinetic model for paclitaxel. J Clin Oncol 2001; 19:4065-4073.
3. Barre J, Didey F, Delion F, Tillement JP. Problems in therapeutic drug monitoring: free drug level monitoring. Ther Drug Monit 1988; 10:133-143.
4. Sparreboom A, van Zuylen L, Brouwer E, Loos WJ, De Bruijn P, Gelderblom H, et al. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res 1999; 59:1454-1457.
5. Gelderblom H, Mross K, ten Tije AJ, Behringer D, Mielke S, Van Zomeren DM, et al. Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusion. J Clin Oncol 2002; 20:574-581.
6. Brouwer E, Verweij J, Hauns B, Loos WJ, Nooter K, Mross K, et al. Linearized colorimetric assay for Cremophor EL: application to pharmacokinetic after 1-hour paclitaxel infusions. Anal Biochem 1998; 261:191-202.
7. Brouwer E, Verweij J, de Bruijn P, Loos WJ, Pillay M, Buijs D, et al. Measurement of fraction unbound paclitaxel in human plasma. Drug Metab Dispos 2000; 28:1141-1145.
8. Sparreboom A, de Bruijn P, Nooter K, Loos WJ, Stoter G, Verweij J. Determination of paclitaxel in human plasma using single solvent extraction prior to isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection. J Chromatogr B 1998; 705:159-164.
9. Baker SD, Zhao M, Zabelina Y, Donehower RC, Wolff AC. Rapid and sensitive method for the determination of docetaxel in human plasma using high-performance liquid chromatography-tandem mass spectrometry (LC-MS-MS). Proc Am Ass Cancer Res 2001; 42:459 (abstr 2059).
10. Sparreboom A, Zhao M, Brahmer JR, Verweij J, Baker SD. Determination of the docetaxel vehicle, polysorbate 80, in patient samples by liquid chromatography-tandem mass spectrometry. J Chromatogr B 2002; 773:183-190.
11. Sparreboom A, Wolff AC, Verweij J, Zabelina Y, Van Zomeren DM, McIntire GL, et al. Disposition of DHA-paclitaxel, a novel taxane, in blood: in vitro and clinical pharmacokinetic studies. Clin Cancer Res 2003; 9:151-159.
12. Rowinsky EK, Burke PJ, Karp JE, Tucker RW, Ettinger DS, Donehower RC. Phase I and pharmacodynamic study of taxol in refractory acute leukemias. Cancer Res 1989; 49:4640-4647.
13. Heimans JJ, Vermorken JB, Wolbers JG, Eeltink CM, Meijer OW, Taphoorn MJ, et al. Paclitaxel (Taxol) concentrations in brain tumor tissue. Ann Oncol 1994; 5:951-953.
14. Glantz MJ, Choy H, Kearns C, Mills PC, Wahlberg LU, Zuhowski EG, et al. Paclitaxel disposition in plasma and central nervous systems of humans and rats with brain tumors. J Natl Cancer Inst 1995; 87:1077-1081.
15. O'Boyle KP, Wang Y, Schwartz EL, Regl DL, Einzig A, Dutcher JP, et al. Development of two radioimmunoassays to detect paclitaxel in sera and in cerebrospinal, ascitic and pleural fluids. Cancer 1997; 79:1022-1030.
16. Tseng SH, Bobola MS, Berger MS, Silber JR. Characterization of paclitaxel (Taxol) sensitivity in human glioma- and medulloblastoma-derived cell lines. Neuro-Oncology 1999; 1:101-108.